Inventor
Gerd Ritter
Inventor
New York, NY, US
Overview
Patents· 47 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07KPeptides24%
A61KPreparations for medical, dental or toiletry purposes23%
G01NInvestigating or analysing materials by determining their chemical or physical properties10%
C12NMicroorganisms or enzymes6%
Y02ATechnologies for adaptation to climate change5%
C07HSugars3%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%
C07CAcyclic or carbocyclic compounds1%
PatentTitleYear
11,013,802Anti-CTLA-4 antibodies and methods of use thereof202110,912,831Anti-CTLA-4 antibodies and methods of use thereof202110,836,830Antibodies and methods of use thereof202010,829,559Anti-GITR antibodies and methods of use thereof202010,800,849Anti-GITR antibodies and methods of use thereof202010,626,181Nucleic acids encoding anti-OX40 antibodies202010,577,426Anti-GITR antibodies and methods of use thereof202010,479,833Anti-CTLA-4 antibodies and methods of use thereof201910,450,373Anti-PD-1 antibodies and methods of use thereof201910,385,138Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy201910,323,091Anti-PD-1 antibodies and methods of use thereof201910,280,226Anti-GITR antibodies and methods of use thereof201910,259,882Anti-OX40 antibodies201910,155,818Anti-GITR antibodies and methods of use thereof201810,144,779Anti-CTLA-4 antibodies and methods of use thereof20189,701,755'Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy'20179,562,102'Specific binding proteins and uses thereof'20179,260,524'Specific binding proteins and uses thereof'20169,072,798'Specific binding proteins and uses thereof'20159,045,533'Membrane transporter NaPi2b (SCL34A2) epitope antibodies'20158,603,474'Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy'20138,541,202'Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein'20138,440,807'A34 and A33-like 3 DNA protein, antibodies thereto and methods of treatment using same'20138,357,373'Methods for stimulating an immune response using bacterial antigen delivery system'20138,334,408'Analogs of alpha galactosylceramide and uses thereof'20128,188,313'Analogs of alpha galactosylceramide and uses thereof'20128,173,102'Tame based chelators and uses thereof'20128,142,786'Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein'20128,039,670'Analogs of alpha galactosyceramide and uses thereof'20117,888,100'Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein'20117,780,947'Tame based chelators and uses thereof'20107,589,180'Specific binding proteins and uses thereof'20097,521,543'A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same'20097,115,729'Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53'20066,723,832'Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof'20046,652,853'Method for treating cancer using A33 specific antibodies and chemotherapeutic agents'20036,346,249'Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products'20026,342,587'A33 antigen specific immunoglobulin products and uses thereof'20026,291,235'Isolated nucleic acid which encodes protein which binds to A33 antibody'20016,190,640'Method for treating neoplasia using humanized antibodies which bind to antigen A33'20016,057,115'Process for producing GM2 specific antibodies'20005,977,329'Methods of synthesizing GM3'19995,854,007'Process for producing GM1 specific antibodies'19985,851,526'Methods of treating colon cancer utilizing tumor-specific antibodies'19985,756,695'Methods of synthesizing GM2'19985,712,369'Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein'19985,102,663'Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3'1992Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1992–2021Based in New York, NY, US· patent location history
1998–2017Patents assigned to LUDWIG INST CANCER RES (25)· patent assignee history
2002–2021Patents assigned to MEMORIAL SLOAN KETTERING CANCER CENTER (15)· patent assignee history
2012–2015Patents assigned to RITTER GERD (10)· patent assignee history
2013–2021Patents assigned to LUDWIG INST FOR CANCER RES LTD (19)· patent assignee history
2018–2021Patents assigned to AGENUS INC (14)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| LUDWIG INST CANCER RES | 25 | 1998–2017 |
| LUDWIG INST FOR CANCER RES LTD | 19 | 2013–2021 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 15 | 2002–2021 |
| AGENUS INC | 14 | 2018–2021 |
| RITTER GERDself | 10 | 2012–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| New York, New York, US | 47 | 1992–2021 |